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Background: The purpose of this study was to assess the accuracy of ovulation detection 
by the DuoFertility® monitor compared with transvaginal ultrasound in infertile women with 
regular menstrual cycles.
Methods: Eight infertile patients, aged 27–40 years, with a body mass index of 19–29,  regular 
menses, normal ovaries on pelvic ultrasound scan, and normal early follicular luteinizing 
 hormone (LH), follicle-stimulating hormone, and prolactin were recruited from infertility clin-
ics in primary and secondary care for this pilot, prospective, observational study. The patients 
were asked to use the DuoFertility monitor for the whole cycle, with investigators and patients 
blind to DuoFertility data. Daily urine LH monitoring commenced on cycle day 8, with daily 
transvaginal ultrasound following the first positive LH until ovulation was observed. Ovulation 
was further confirmed by serum progesterone. The main outcome measure was detection of 
ovulation by the DuoFertility monitor, and correlation between day of ovulation assessed by 
DuoFertility and ultrasound.
Results: DuoFertility identified ovulation as having occurred within one day of that determined 
via ultrasound in all cycles. The sensitivity of ovulation detection was 100% (95% confidence 
interval 82–100). The specificity could not be concluded from the data.
Conclusion: In infertile women with regular cycles, the DuoFertility monitor appears to 
 accurately identify ovulatory cycles and the day of ovulation.
Keywords: fertility monitor, ovulation, infertility, ultrasound scan, urinary luteinizing 
hormone
Introduction
Infertility affects 13%–15% of couples worldwide.1 The use of fertility monitors is 
widespread in this population. However, these monitors are generally tested on a group 
of fertile couples to assess their accuracy2–6 rather than on a population of infertile 
couples.
Guidelines from the UK National Institute of Health and Clinical Excellence state 
that the use of basal body temperature (BBT) charts to confirm ovulation does not 
reliably predict ovulation and is not recommended for infertile couples.7 Several stud-
ies have assessed the accuracy of traditional BBT methods compared with ovulation 
(luteinizing hormone) tests by comparing them with transvaginal ultrasound. These 
studies have reported a lack of reliability of traditional BBT measurements.8,9
The DuoFertility® monitor (Cambridge Temperature Concepts Ltd, Cambridge, 
UK) is a new electronic device that has been developed to help couples identify 
their most fertile days to plan intercourse, and has been used in the UK since 2009.10 
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The DuoFertility monitor measures temperature, heat flow, 
and movement through an axillary sensor worn by the 
patient, as seen in Figure 1. This allows quality of sleep to be 
inferred, and therefore the best time of the night to measure 
resting BBT can be identified. Thousands of measurements 
are taken every 24 hours and the patient can visualize a 
summary temperature on their software showing the most 
representative temperature of the night. It is plausible that 
continuous temperature monitoring during the night may 
offer a more representative indication of BBT than a single 
temperature measurement upon waking. In addition, a con-
tinuous body-worn sensor may increase compliance beyond 
traditional daily oral measurement on waking, as there is no 
requirement on the part of the user to remember to use the 
device at any specific time.
The primary aim of this pilot study was to compare the 
ability of the DuoFertility monitor to detect ovulation with 
that of the gold standard method of transvaginal ultrasono-
graphy, supplemented by serum progesterone estimation, in a 
population of infertile women with regular menstrual cycles. 
A secondary aim was to compare the date of ovulation as 
estimated by the monitor with the date of ovulation as judged 
on serial transvaginal ultrasound sonography by an experi-
enced operator. The study was not designed to compare this 
device with other methods of ovulation detection (BBT or 
ovulation tests) as these are not the gold standard. This was 
a pilot study examining the value of this test and therefore 
needed to be compared with the gold standard.
Materials and methods
The study (Clinical trial registration number NCT01360684, 
A091932, 10/H0308/35) was approved by the Cambridgeshire 
Central Research Ethics Committee. Female partners of 
couples presenting with infertility were recruited from the 
Fertility Clinic at the Rosie Hospital, Cambridge and the 
Saffron Walden Community Hospital, Saffron Walden (both 
secondary care), and the Newnham Walk Surgery, Cambridge 
(primary care). The inclusion criteria were as follows: trying 
to conceive for at least 12 months; female aged 18–44 years; 
female body mass index 19–29; and regular menstrual cycles 
ranging from 21 to 35 days with less than 7 days variation 
between cycles in the last 12 months.
Patients who were considered likely to be eligible for 
the study were provided with preliminary information after 
their consultation and asked to contact the investigators 
if they wished to consider participation in the study. Patients 
who established contact with the investigators were given 
further information and underwent a screening assessment 
(pelvic ultrasound scan and early follicular phase follicle-
stimulating hormone, luteinizing hormone, and prolactin). 
The following exclusion criteria were applied: any diagnosed 
systemic illnesses, including but not restricted to thyroid dis-
ease, diabetes, or inflammatory diseases; polycystic ovarian 
syndrome; endometriosis or other pelvic pathology (including 
proven tubal disease); taking steroids, including oral contracep-
tives or anti-inflammatory drugs; ovaries not clearly visualized 
on transvaginal ultrasound; and unwilling to undergo transvagi-
nal ultrasound scan or to wear the DuoFertility monitor.
A total of eight patients were recruited for the study. 
 Written consent was obtained from all participants in 
 accordance with the approval from the research ethics 
committee. Women were advised to start testing their first 
morning sample of urine using luteinizing hormone tests 
(ClearBlue® ovulation test; Swiss Precision Diagnostics 
GmbH, Geneva, Switzerland) on day 8 of their cycle and to 
come for an ultrasound scan on the day of the first  positive 
ovulation test. Transvaginal ultrasound scanning was repeated 
daily until evidence of ovulation was obtained in the form of 
collapse of a previously seen follicle. A maximum of four 
ultrasound scans per cycle was performed on each patient. 
The presence or absence of free fluid in the pouch of Douglas 
was noted. Serum progesterone was measured 3–10 days 
after the presumed date of ovulation. All but three scans of 
Figure 1 DuoFertility® sensor.
Note: DuoFertility® (cambridge Temperature concepts ltd, cambridge, UK).
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a total of 40 scans were performed by the same operator, 
which should limit the subjectivity of interpretation that has 
been reported in several studies.11,12 Transvaginal scans were 
performed on an ultrasound machine used for monitoring 
ovarian response in assisted conception cycles (CoreVision 
Pro model number SSA-350A; Toshiba, Tokyo, Japan).
Patients were asked to wear the DuoFertility monitor 
continuously from day 1 of their menstrual cycle. The moni-
tor could be removed for bathing/swimming if the patient 
wished to do so, but this was not required. Data from the 
monitor were downloaded to the DuoFertility handheld 
monitor and the data were automatically transferred to 
the DuoFertility servers. The DuoFertility monitor uses 
proprietary algorithms to automatically identify the date of 
ovulation for a particular cycle and patient. Although the 
DuoFertility monitor can accept additional user input such 
as home luteinizing  hormone tests or cervical mucus, no 
data beyond the temperature and movement data collected 
by the sensor were used in this study. The date of ovulation 
generated by the monitor was used as the date of ovulation 
identified by DuoFertility.
Patients and investigators performing the ultrasound scans 
were blind to the results obtained by the DuoFertility  monitor 
until the end of the study. Interpreters of the DuoFertility 
data were blind to the ultrasound and progesterone results. 
Following unblinding, the following comparisons were made: 
ovulation identified by DuoFertility versus ovulation identi-
fied by serial transvaginal ultrasound supplemented by serum 
progesterone measurement; and date of ovulation identified 
by DuoFertility versus date of ovulation identified by serial 
transvaginal ultrasound.
Statistical analysis was performed using the R  statistical 
package.13 As recommended by Brown et al14 for the 
 challenging case of small n and P∼1, the Wilson score 
interval15 was used to estimate the confidence interval for 
sensitivity in this study. It should be noted that, in such 
analysis, each menstrual cycle is considered independently, 
which may not be correct in cases where women contributed 
more than one cycle to the study.
Results
The inclusion of patients for this study is detailed in Figure 2. 
Ten patients gave consent, of whom eight eventually took part 
in the study. One of the two patients who consented but did 
not take part in the study conceived in the cycle before she 
was due to start and the other withdrew for personal reasons. 
One of the participants contributed to one included cycle 
(she became pregnant in the first cycle), three participants 
contributed to three included cycles, and two participants 
contributed to four included cycles.
A total of 35 cycles was collected, of which 17 were 
excluded from analysis and 18 cycles were included. The 
reasons for excluding these cycles were as follows: six cycles 
were used to set up the protocol and were not included in the 
analysis because no data were collected on the DuoFertility 
monitor. Eight cycles could not be included because the 
patients did not come in for ultrasound scans at the required 
time. Two cycles were not included because the patients did 
not use the DuoFertility monitor.
For all cycles included in this study, at least one scan was 
performed prior to ovulation, and ovulation was documented 
by follicular collapse on subsequent measurement. Free fluid 
in the pouch of Douglas was documented in nine cycles. 
For 16 of the cycles, a blood test 7 days following ovulation 
was performed to measure the progesterone level, with all 
results above 19.8 nmol/L confirming ovulation. The other 
two patients did not come for their blood test.
In every cycle for which ultrasound identified ovulation, 
DuoFertility also identified that ovulation had occurred. 
Although the data imply 100% sensitivity (ie, a 0% 
 false-negative rate), it is possible to calculate the expected 
worst-case sensitivity from the observed data. The lower 
bound of a Wilson score15 95% confidence interval for the 
sensitivity as a binomial parameter can be calculated as 82%, 
implying a worst-case sensitivity of 82%. This assumes sta-
tistical independence of cycles, which may not be correct 
as some women contributed multiple cycles to the study. 
There were no anovulatory cycles observed in this data set, 
as patients who do not ovulate are not the target user group 
of the DuoFertility monitor, so a measure of specificity (ie, 
false-positive rate) is not possible from the data collected in 
this pilot study.
Figure 3 shows the temporal correlation between the 
day of ovulation as identified by ultrasound scanning and 
8 women 35 cycles 
18 cycles
included 
17 cycles
excluded 
6 cycles
for protocol set up 
8 cycles
patient did not come
 for scans 
2 cycles 
patient did not use 
DuoFertility
16 cycles
patient came for 
serum progesterone
2 cycles
patient did not come
 for serum 
progesterone
Figure 2 Patient inclusion.
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the DuoFertility monitor. In Figure 3, “–1” indicates that 
the DuoFertility monitor has identified ovulation on the day 
between the last scan showing the dominant follicle and the 
scan showing collapse of the follicle. “0” indicates that 
the DuoFertility monitor identified ovulation on the day of the 
follicle collapse. Finally “+1” indicates that the DuoFertility 
monitor identified ovulation as occurring between the day of 
collapse of the follicle and the following day. The result shows 
a 100% correlation of the results at ±24 hours, which is the 
best resolution that could be archived using our  experimental 
design.
Discussion
The aim of this study was to compare the accuracy of 
 ovulation detection by the DuoFertility monitor with that 
of transvaginal ultrasonography. Ovulation was further 
 confirmed by serum progesterone measurements. This 
appears to be the first study looking at the accuracy of a 
home  fertility monitor performed in a group of infertile 
patients. The authors believe that this is an important dis-
tinction because patients using fertility monitors are (in the 
vast majority of cases) infertile, and thus may not be well 
represented by the general (fertile) population.
The data suggest that such a monitoring technique may 
be useful for identifying ovulation in infertile women with 
regular cycles. However, the use of fertility monitors in 
general should not be a substitute for regular intercourse as 
recommended by the UK National Institute of Health and 
Clinical Excellence guidelines.
In this study, we used collapse of the follicle as seen on 
transvaginal ultrasound imaging as a marker of ovulation, and 
use this as a reference point to compare the ovulation date 
provided by the DuoFertility monitor. Daily ultrasound 
imaging is routinely used in assisted reproductive technol-
ogy cycles to monitor growth of the follicles, and can also be 
used in natural cycles to identify the occurrence of ovulation. 
Interpretation of the images can be subjective, and when pos-
sible should be performed by the same operator.16 The use 
of transvaginal ultrasonography is recommended for greater 
accuracy and reliability than is possible with abdominal 
 ultrasonography.17 This pilot study shows that the results 
for the DuoFertility, which are based on high-resolution 
temperature measurements, appear to identify ovulation as 
accurately as a series of transvaginal ultrasound scans.
This study challenges the received wisdom that body 
temperature measurement is not useful for monitoring 
 ovulation. Even though previous studies have not found 
BBT to be a reliable method of ovulation detection, techno-
logical advances as represented by the DuoFertility monitor 
may mean that this parameter should be re-examined for its 
clinical value. It is important to note that use of fertility moni-
tors has been implicated as a potential cause of emotional 
stress.18 However, this relates to methods based on manual 
recording of temperature or urinary luteinizing hormone by 
the patient,19,20 rather than this novel method in which data 
are recorded automatically while the patient is asleep.
The authors acknowledge that there are several limitations 
to this study design. Firstly, the study was restricted to 
0
−2 −1 0 1 2
2
4
6
N
u
m
b
er
 o
f 
cy
cl
es
 o
b
se
rv
ed 8
10
12
Correlation between ultrasound scan and DuoFertility
Difference in date of ovulation determined by DuoFertility compared to ultrasound (days)
Figure 3 correlation between ultrasound scan and DuoFertility®.
Note: DuoFertility® (cambridge Temperature concepts ltd, cambridge, UK).
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women with regular cycles and no anovulatory cycles were 
observed, as a result of which it was not possible to judge 
the specificity of ovulation detection (false-positive rate) by 
DuoFertility. Secondly, both the daily ultrasound measure-
ments and the DuoFertility monitor have a resolution of 
24 hours, so the resolution of the results cannot be more pre-
cise than ±24 hours. Finally, the number of patients included 
in the study was small. This is partly due to the nature of the 
population of patients from which the subjects were recruited, 
as many eligible patients in the hospital fertility clinic chose 
to move to in vitro fertilization rather than participate in the 
study, and the fact that a series of daily ultrasound scans can 
be relatively invasive. As this was a pilot study, we did not 
perform a formal sample size calculation.
Despite these limitations, this study suggests that the 
DuoFertility monitor, possibly as a result of increased 
frequency of temperature measurement, appears to be an 
accurate method for ovulation detection in infertile women 
with regular cycles, and comparable with the gold standard of 
transvaginal ultrasound scanning supplemented with serum 
progesterone. The use of new technology to continuously 
monitor temperature in a convenient manner (DuoFertility is 
a small sensor worn under the arm on a small adhesive pad) 
allows accurate identification of the date of ovulation with 
minimal invasiveness. Further investigations to overcome 
the limitations of this pilot study, in particular relating to the 
size of the study, number of cycles per woman monitored, 
inclusion of women with anovulatory cycles, and inclusion 
of women with irregular cycles, should be considered. We 
are currently planning a further trial of this device in women 
with irregular cycles who may or may not be ovulatory.
DuoFertility could provide an alternative means of 
monitoring ovulation in some particular cases. It has been 
 suggested by the American Society for  Reproductive 
 Medicine practice committee21 that couples who have 
infrequent intercourse may in particular benefit from the use 
of devices that can predict or determine the time of ovulation. 
Because DuoFertility is a noninvasive method for the patient 
to use at home, with data transmitted over the Internet, we 
speculate that some patients may find it at least as, if not more, 
acceptable than a more clinical method such as transvaginal 
ultrasound monitoring, with potential benefits for patient 
compliance and data collection.
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